Im­mune Reg­u­la­tion makes Pe­ter Green­leaf chair­man and as­sem­bles a quin­tet of new ex­ecs; Bob Cough­lin moves on from Mass­Bio to JLL

→ In Sep­tem­ber, Im­mune Reg­u­la­tion raked in $53.4 mil­lion in a Se­ries B for two pro­grams in rheuma­toid arthri­tis and asth­ma. This week, the British biotech has named Au­rinia CEO Pe­ter Green­leaf chair­man of the board while an­nounc­ing five ap­pointees that have joined CEO Jonathan Rig­by’s crew. Green­leaf took the reins at Au­rinia — which just yes­ter­day struck up an agree­ment with Ot­su­ka to com­mer­cial­ize vo­closporin in Japan and Eu­rope — in April 2019. He was al­so the CEO of Cere­cor and Su­cam­po Phar­ma­ceu­ti­cals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER